High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients

Cao et al. (Sun,) studied this question.

www.synapsesocial.com/papers/6a086a2aab15ea61dee8d354 — DOI: https://doi.org/10.1080/2162402x.2019.1629258

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses· 2014 · 17,872 citations
2. Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA).· 2017 · 28 citations
3. Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227· 2018 · 12 citations
4. Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026· 2017 · 93 citations
5. Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer· 2018 · 4 citations